Johnson & Johnson (J&J)

See the following -

CEO Roundtable On Cancer Launches The Project Data Sphere Initiative, A New Data Sharing And Analytic Platform For Cancer Patient Benefit

Press Release | CEO Roundtable on Cancer , SAS, Sage Bionetworks | April 8, 2014

Project Data Sphere, LLC (PDS), an independent not-for-profit initiative of the CEO Roundtable on Cancer’s Life Sciences Consortium (LSC), announced today the launch of a new data sharing platform (www.ProjectDataSphere.org), with the goal of advancing research to improve the lives of cancer patients and their families around the world...

Read More »

Data Sharing, EHR Interoperability Keys To Improving Clinical Trials

Katie Dvorak | FierceHealth IT | July 9, 2014

As the complexity of clinical trials continues to grow, increased data sharing and interoperability will become more important, according to panelists participating at a House Energy and Commerce Committee hearing Wednesday...

Read More »

In Stunning Win For Open Science, Johnson & Johnson Decides To Release Its Clinical Trial Data To Researchers

Matthew Herper | Forbes Magazine | January 30, 2014

Today, Johnson & Johnson JNJ +0.07% is taking a major step toward changing that, not only for drugs like the blood thinner Xarelto or prostate cancer pill Zytiga but also for the artificial hips and knees made for its orthopedics division or even consumer products. “You want to know about Listerine trials? They’ll have it,” says Harlan Krumholz of Yale University, who is overseeing the group that will release the data to researchers.

Read More »

In Stunning Win For Open Science, Johnson & Johnson Decides To Release Its Clinical Trial Data To Researchers

Matthew Herper | Forbes | January 30, 2014

Drug companies tend to be secretive, to say the least, about studies of their medicines. For years, negative trials would not even be published. Except for the U.S. Food and Drug Administration, nobody got to look at the raw information behind those studies. The medical data behind important drugs, devices, and other products was kept shrouded. Read More »

J&J Sets Drug Data Free In ‘YODA’ Collaboration With Yale

Drew Armstrong | Bloomberg | January 31, 2014

Johnson & Johnson (JNJ) will give academics access to data on clinical trials, a move that may prompt more companies to do the same. Read More »

Johnson & Johnson Announces Clinical Trial Data Sharing Agreement With Yale School of Medicine

Press Release | Johnson & Johnson, Yale School of Medicine | January 30, 2014

Johnson & Johnson today announced that its subsidiary, Janssen Research and Development, LLC, has entered into a novel agreement with Yale School of Medicine's Open Data Access (YODA) Project that will extend its commitment to sharing clinical trials data to enhance public health and advance science and medicine.  

Read More »

Transitioning To Open Systems In Drug Discovery

John Wilbanks | FasterCures | October 18, 2013

Bringing the ideas of “open source” into the pharmaceutical process is far from simple. It requires a careful understanding both of the realities of open source as a software development process well as the realities of therapy research, development, and regulatory approval. Read More »

Yale Program's Agreement With Johnson & Johnson Allows Broad Access To Clinical Trial Data

Press Release | Yale University Open Data Access (YODA) Project, Johnson & Johnson (J&J) | January 30, 2014

In a move that promotes open science, the Yale University Open Data Access (YODA) Project has entered an agreement with Johnson & Johnson that will enable scientists around the world to gain access to the company's clinical trial data assets. Read More »

Yale Program’s Agreement With Johnson & Johnson Allows Broad Access To Clinical Trial Data

Karen N. Peart | Yale News | January 30, 2014

In a move that promotes open science, the Yale University Open Data Access (YODA) Project has entered an agreement with Johnson & Johnson that will enable scientists around the world to gain access to the company’s clinical trial data assets. Read More »